NOV-1776
Not explicitly stated (likely General Pain/Joint Inflammation)
Phase 2Active
Key Facts
Indication
Not explicitly stated (likely General Pain/Joint Inflammation)
Phase
Phase 2
Status
Active
Company
About Novilla Pharmaceuticals
Novilla Pharmaceuticals is a private, pre-revenue biotechnology company leveraging a proprietary AI-driven drug delivery platform to design localized therapeutics. Its lead candidate, NOV-1776, has recently completed human clinical trials, demonstrating a 212% increase in efficacy over standard of care with minimal systemic exposure and no gastrointestinal adverse events. The company is targeting multiple therapeutic areas including gout, general pain, and joint inflammation, with a seasoned leadership team combining deep expertise in neurology, pain therapeutics, chemistry, and AI.
View full company profile